GLSI
Greenwich Lifesciences Inc
NASDAQ: GLSI · HEALTHCARE · BIOTECHNOLOGY
$24.13
-6.00% today
Updated 2026-06-05
Market cap
$326.59M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$8 – $34
Volume
0.1M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.8
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
29.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$47.50
+96.85%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 29.86 — safe zone
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-4.70M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $3558.00 |
| Net income | $-7.83M | $-8.89M | $-17.41M | $-19.36M | $-5.66M |
| EPS | — | — | — | — | $-1.61 |
| Free cash flow | $-6.20M | $-6.48M | $-7.27M | $-9.91M | $-4.70M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-13 | PATEL, SNEHAL | Buy | 1,800 | $29.83 |
| 2026-01-12 | PATEL, SNEHAL | Buy | 2,900 | $27.54 |
| 2025-12-31 | PATEL, SNEHAL | Buy | 4,300 | $21.36 |
Peer comparison
Smart narrative
Greenwich Lifesciences Inc trades at $24.13. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 29.86, it sits in the safe zone.
Frequently asked questions
What is Greenwich Lifesciences Inc's stock price?
Greenwich Lifesciences Inc (GLSI) trades at $24.13.
Is Greenwich Lifesciences Inc overvalued?
Greenwich Lifesciences Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Greenwich Lifesciences Inc (GLSI)?
The 12-month analyst consensus target is $47.50, about 96.9% above the current $24.13. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Greenwich Lifesciences Inc's Altman Z-Score is 29.86, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-891.35%
Beta1.38
50D MA$24.93
200D MA$18.59
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—